Swedish national prostate biopsy and MRI report template.

<p>1) Side (sagittal) view of the prostate, 2) ventral (coronal) view of the prostate, 3) transverse (axial) sections A-C of pictures 1) and 2). The study participants used this diagram without the colour lines to plot the prostate tumor location. The correctly plotted tumor location of case 3 is shown in the diagram (pink areas). For the scoring system picture 1) was divided in an anterior and posterior half (green line), picture 2) in a right and left half (red line) and picture 3 A-C in quadrants (blue, orange, yellow, turquoise). (MRI) magnetic resonance imaging; (SV) seminal vesicle; (a) anterior; (p) posterior; broken lines in picture 1) mark the urethra.</p

Scoring results (median with IQR) for group 1 (expert urologists) and group 2 (medical students), sub-classified for pictures 1–3 of the prostate template (side (sagittal) view, ventral (coronal) view, overall transverse (axial) view (ABC)) (s. Fig 1) in information tool A (written MRI report), information tool B (3D printed model) and information tool C (MRI presentation in MDT).

<p>Scoring results (median with IQR) for group 1 (expert urologists) and group 2 (medical students), sub-classified for pictures 1–3 of the prostate template (side (sagittal) view, ventral (coronal) view, overall transverse (axial) view (ABC)) (s. <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0199477#pone.0199477.g001" target="_blank">Fig 1</a>) in information tool A (written MRI report), information tool B (3D printed model) and information tool C (MRI presentation in MDT).</p

Summarized rates (%) of (A) major mistakes (s. Table 4A1) and (B) rates (%) of complete major accuracy (0% major mistakes) (s. Table 4A2) in group 1 (expert urologists) and group 2 (medical students) subdivided for information tools A-C.

<p>Summarized rates (%) of (A) major mistakes (s. <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0199477#pone.0199477.t004" target="_blank">Table 4A1</a>) and (B) rates (%) of complete major accuracy (0% major mistakes) (s. <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0199477#pone.0199477.t004" target="_blank">Table 4A2</a>) in group 1 (expert urologists) and group 2 (medical students) subdivided for information tools A-C.</p

Prostate cancer lesion of case 3 according to 3D printed prostate model, MRI and prostate template.

<p>In (1) corresponding side (sagittal) views and (2) according to ventral (coronal) views in 3D printed prostate model and prostate template and different sequences of the corresponding axial view in MRI (corresponds to broken line in section B). (SV) seminal vesicle, (a) anterior, (p) posterior. Arrows indicate prostate cancer in MRI.</p

Polyclonal rabbit anti GPGRAPI-GST serum: A) After immunization the polyclonal antiserum but not a control protein (scrambled sequence) strongly binds to immobilized synthetic GPGRAPI.

<p>Pre-immune rabbit serum (white column) served as negative control and did not bind to either peptides. B) Binding of the polyclonal antiserum to immobilized GPGRAPI-GST fusion protein is competitively inhibited by synthetic GPGRAPI- but not by the control peptide. Preimmune serum from the same rabbit served as negative control. Error bars represent standard deviation of triplicates, ** indicates p <0.001</p

Ubiquitin is specifically recognized by the immunized rabbit antiserum and the index patient serum as determined by binding inhibition.

<p>A) Addition of 600μg GPGRAPI peptide (p<0,01), but not a control peptide significantly decreases binding of the immunized serum to Ubiquitin. B) Similarly, serum from the index patient (black columns) was competitively inhibited. A human control serum (white columns) bound lower than the index patient serum and was not inhibited by GPGRAPI peptide. Error bars represent standard deviation of triplicates, * indicates p <0.01.</p

An Anti-Ubiquitin Antibody Response in Transitional Cell Carcinoma of the Urinary Bladder - Table 2

<p>An Anti-Ubiquitin Antibody Response in Transitional Cell Carcinoma of the Urinary Bladder</p> - Table

An Anti-Ubiquitin Antibody Response in Transitional Cell Carcinoma of the Urinary Bladder - Table 1

<p>An Anti-Ubiquitin Antibody Response in Transitional Cell Carcinoma of the Urinary Bladder</p> - Table

Identification of the corresponding antigen to the peptide sequence GPGRAPI.

<p>Protein isolates of the human urothelial cancer bladder cell line T24 was harvested, lysed and fractionated. (N = nuclear, C = cytosolic fraction, M = protein marker). A) Western Blot, stained with preimmune (left gel) and the immunized (right gel) rabbit serum. B) Corresponding gel before (left gel) and after excision (right gel) of the recognized bands for MALDI analysis.</p

ELISA analysis of anti Ubiquitin titers. Left axis depicts absorbance/optical density (O.D.) at 620nm.

<p>A) TCC patients (black columns) have significant higher titers compared to non TCC patients (grey columns) (p<0.001). B) Titers from patients undergoing BCG immunotherapy for high risk TCC do not differ when comparing responder (black columns) to non responder (white columns). Bars represent titer changes against Ubiquitin during BCG-therapy. Inlets depict results of Mann Whitney U test (box and whiskers plots with maximum and minimum range).</p